贝伐单抗(avastin)与FOLFIRI联用能延长CRC患者的PFS和OS 贝伐单抗(avastin)是是一种重组的人鼠嵌合型单抗,主要通过抑制肿瘤新生血管形成和促进肿瘤血管退化而产生抗肿瘤作用, 通过与其他抗肿瘤化疗药物联用而产生增敏作用。2004年的《新英格兰杂志》报道了一个有关贝伐单抗联合IFL方案(伊立替康+5-Fu静推+亚叶酸钙)...
目的:比较Avastin(贝伐单抗)联合FOLFIRI化疗方案(伊立替康+亚叶酸钙+5-氟尿嘧啶)与单用FOLFIRI化疗方案二线治疗晚期结肠癌的临床疗效.方法:28例经组织病理学证实的晚期结肠癌患者,随机分组.Avastin联合FOLFIRI治疗组12例:Avastin后于化疗药物使用,化疗后第二天使用,用量为5mg/kg.首次应用Avastin静脉滴注90min以上,如果...
[8]Loupakis F,Bria E,Vaccaro V,et al.Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer:meta-analysis of randomized clinical trials[J].J Exp Clin Cancer Res,2010,26(29):58. [9]王继荣,李娟,陆彬彬,等.Avastin联合FOLFIRI治疗晚期肠癌...
英文缩略词索引 英文缩写 CRCBV VEGF VEGFR FDA OS PFS 英文全称 Colorectal cancer 英文缩略词索引 Bevacizumab/Avastin vascular endothelialgrowth factor 中文全称 结直肠癌 贝伐单抗 血管内皮细胞生长因子 vascular endothelial growth factor receptor 血管内皮生长因子受体 U.S.Food and Drug Administration, 美国食品与...
FOLFIRI化疗方案联合贝伐单抗治疗转移性结直肠癌的临床观察
The phase 3 component is a 3-arm randomization to EC alone; EC plus mFOLFOX6; or the control arm of bevacizumab (Avastin) plus FOLFIRI, mFOLFOX6, or capecitabine and oxaliplatin (CAPOX). Cohort 3 is randomizing patients to either EC/FOLFIRI or FOLFIRI plus bevacizumab. Microscopic, ...
FOLFIRI is a chemotherapy regimen that consists of irinotecan, infusional 5-FU, and leucovorin. It is used in the treatment of previously untreated metastatic colorectal cancer and has shown comparable efficacy to other chemotherapy regimens like FOLFOX. ...
that spot much like it did with the node in her neck and bring her pain relief. This would be good. The other new thing were “polyps in her maxillary antrum (Sinuses)” That could be something simple like the side effects / scaring from the Avastin…. So, what does that all mean ...
(ColorEctalavastiNTRiAlLdh) trial Riccardo Giampieri*,1, Marco Puzzoni2, Bruno Daniele3, Daris Ferrari4, Sara Lonardi5, Alberto Zaniboni6, Luigi Cavanna7, Gerardo Rosati8, Nicoletta Pella9, Maria Giulia Zampino10, Pietro Sozzi11, Domenico Germano3, Vittorina Zagonel5, Carla Codeca` 4, ...
2012年第39卷第19期中国肿瘤临床 贝伐珠单抗联合FOLFIRI方案治疗晚期转移性 结直肠癌患者的临床观察 朱春荣李大鹏熊峰朱彦博宋乐冬陶敏 摘要目的:观察贝伐珠单抗联合化疗治疗晚期转移性结直肠癌患者的近期疗效和毒副反应。方法:回顾性分析38例晚期 转移性结直肠癌患者贝伐珠单抗联合FOLFIRI方案治疗的临床资料,化疗应用4～6...